Şunu aradınız:: hypothalamic (İngilizce - Maltaca)

have uncontrolled pituitary gland or hypothalamic problems
għandek problemi mhux ikkontrollati tal-glandola pitwitarja jew tal-ipotalamu

have uncontrolled pituitary gland or hypothalamic problems.
għandek glandola pitwitarja mhux ikkontrollata jew problemi ipotalamiċi.

in such circumstances hypothalamic pituitary adrenocortical (hpa) axis function should be monitored regularly.
f’ ċirkustanzi bħal dan, il-funzjoni tal-assi ipotalmika-pitwitarja-adrenokortikali (hpa) għandha tiġi mmonitorjata b’mod regolari.

pharmacotherapeutic group: pituitary and hypothalamic hormones and analogues, anterior pituitary lobe hormones and analogues.
kategorija farmakoterapewtika: ormoni u analogi tal-lobu pitwitarju u tal-ipotalamu, ormoni u analogi tal-lobu pitwitarju anerjuri.

pharmacotherapeutic group: pituitary and hypothalamic hormones and analogues, somatostatin and analogues, atc code: h01cb05
kategorija farmakoterapewtika: ormoni u analogy pitwitarji u ipotalamiċi, somatostatin u analogi, kodiċi atc: h01cb05

pharmacotherapeutic group: pituitary and hypothalamic hormones and analogues, somatropin and analogues, atc code: h01 ac 01
kategorija farmakoterapewtika: ormoni u analogi tal-pitwitarja u tal-ipotalamu, somatropin u analogi, kodiċi atc: h01 ac 01

pharmacotherapeutic group: pituitary and hypothalamic hormones and analogues, somatropin and somatropin agonists; atc code: h01ac01
kategorija farmakoterapewtika: ormoni u analogi pitwitarji u ipotalamiċi, somatropin u agonisti ta’ somatropin; kodiċi atc: h01ac01

severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin.
pazjenti b’ defiċjenza severa ta ’ l- ormon tat- tkabbir fiż- żmien ta ’ meta jkunu saru adulti huma definiti bħala pazjenti li għandhom patoloġija pitwitarja ipotalamika magħrufa u mill- inqas defiċjenza waħda magħrufa ta ’ ormon pitwitarju li ma jkunx prolaktin.

in particular, patients should be evaluated for hypothyroidism, adrenocortical deficiency, hyperprolactinemia and pituitary or hypothalamic tumours, and appropriate specific treatment given.
b’mod partikolari, il-pazjenti għandhom ikunu eżaminati għall-ipotirojdiżmu, defiċjenza adrenokortikali, iperprolaktinemija u tumuri pitwitarji jew ipotalamiċi, u għandha tingħata l-kura meħtieġa.

orgalutran is a gnrh antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitive binding to the gnrh receptors in the pituitary gland.
orgalutran huwa antagonist ta' gnrh u jimmodola l-assi ipotalamika-pitwitarja-gonadali, billi jikkompeti biex jintrabat għar-riċetturi tal-gnrh fil-glandola pitwitarja.

in particular, patients should be evaluated for the following: • hypothyroidism • adrenocortical deficiency • hyperprolactinemia and pituitary or hypothalamic tumours
b’ mod partikolari, il- pazjenti għandhom ikunu eżaminati għal: • ipotirojdiżmu • defiċjenza adrenokortikali • iperprolaktinimja jew tumuri pitwitarji jew ipotalamiċi

the patient must have growth hormone deficiency as a result of hypothalamic or pituitary disease, and at least one other hormone deficiency diagnosed (except for prolactin).
il- pazjent irid ikollu defiċjenza tal- ormon tat- tkabbir bħala riżultat ta ’ mard fl - ipotalamu jew fil- pitwitarja, u ta ’ l- inqas dijanjożi ta ’ defiċjenza ta ’ ormon ieħor (minbarra prolactin).

adult onset: patients who have severe growth hormone deficiency associated with multiple hormone deficiencies as a result of known hypothalamic or pituitary pathology, and who have at least one known deficiency of a pituitary hormone not being prolactin.
bidu f’età adulta: pazjenti li għandhom defiċjenza severa ta’ l-ormon tat-tkabbir assoċjata ma’ defiċjenzi multipli tal-ormoni bħala riżultat ta’ patoloġija pitwitarja ipotalamika jew ipotalamika magħrufa u li għandhom mill-inqas defiċjenza waħda magħrufa ta’ ormon pitwitarju li ma jkunx prolaktin.

fluticasone furoate 110 micrograms once daily was not associated with hypothalamic- pituitary-adrenal (hpa) axis suppression in adult, adolescent or paediatric subjects.
110 mikrogrammi ta’ fluticasone furoate darba kuljum ma ġewx assoċjati ma’ hypothalamic-pituitary-adrenal (hpa) axis suppression f’suġġetti adulti, adolexxenti jew pedjatriċi.

in patients with childhood-onset isolated growth hormone deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low insulin-like growth factor-1 (igf-1) concentrations (< 2 standard deviation score (sds)), who may be considered for one test.
f' pazjenti b' defiċjenza iżolata ta 'l- ormon tat- tkabbir li bdiet fit- tfulija (ebda evidenza ta' mard ipotalamiku- pitwitarju jew ta 'radjazzjoni fil- kranju), għandhom jiġu rakkomandati żewġ testijiet dinamiċi, ħlief għal dawk li jkollhom konċentrazzjonijiet baxxi tal- fattur- 1 tat- tkabbir (igf- 1) li jixbah lill- insulina (< 2 punteġġ ta' devjazzjoni standard (sds)), li jistgħu jiġu kkunsidrati għal test wieħed.